Still no weight loss after 3 weeks on Wegovy? Here's why that's normal

Step 1: Understand what the first three weeks are actually for

Wegovy's titration schedule starts at 0.25 mg for the first four weeks, then moves to 0.5 mg, then 1 mg, then 1.7 mg, and finally 2.4 mg, with roughly a month at each level. Three weeks in, you are still on the lowest dose in a five-rung ladder. That isn't a design flaw. The slow start exists because semaglutide's most common side effects (nausea, loose stools, bloating) are sharpest when the medicine is new to your system, and a gentle introduction reduces the chance you need to pause or stop altogether. The 0.25 mg dose was never intended to drive fat loss; it is a settling-in period. Most people who report meaningful appetite changes describe them starting somewhere between weeks four and eight, often after their first or second dose increase. So if three weeks in you feel roughly the same hunger levels as before, that fits the expected pattern almost exactly. You can read more about what happens in the first two weeks on Wegovy for context on the very early phase, the picture at week three is similar but with slightly more adaptation behind you.

Step 2: Rule out what looks like stalled progress but isn't

Scales measure total body mass, water, food in transit, muscle, fat, and the contents of your bladder. They do not measure fat loss in isolation. Semaglutide slows gastric emptying, which means food moves through your digestive system more slowly than usual. That alone can add a kilogram or two to your morning weight compared with before treatment, even if fat is quietly reducing underneath. Hormonal fluctuations, a change in salt intake, a long flight, or starting to drink more water can each shift the number by 1–3 kg within a single day. Weighing yourself at the same time each morning, after the bathroom and before eating, and then averaging across a week gives a cleaner signal than any single daily reading. Many people find that a measurement they took on day one (waist circumference with a tape measure) tells a more accurate early story than the scales do. If you are curious about how week-by-week progress typically looks as the doses increase, the experience at six weeks on Wegovy is worth reading alongside this page.

Step 3: Know the real timeline the evidence supports

The STEP 1 trial (published in the New England Journal of Medicine) followed 1,961 adults on semaglutide 2.4 mg over 68 weeks and found an average body-weight reduction of around 15%. That figure accumulated over more than a year, with the sharpest monthly losses typically occurring once participants reached the 1.7 mg and 2.4 mg maintenance doses, not in the first three weeks. The NHS medicines page for semaglutide is clear that weight loss with this treatment is gradual and that the full effect takes months to develop. Feeling impatient at week three is understandable, it takes courage to start treatment, adjust your routine and then see no change on the scales. But the data is consistent: for people who stay with the full titration, meaningful loss tends to follow. The question is rarely whether semaglutide is working; it's usually whether you've reached the dose where it works for you yet. Reporting from Reuters on Wegovy offers useful wider context on how the treatment has performed across real-world populations. You can read more about how weight loss on Wegovy typically progresses as doses increase.

Step 4: Identify the situations that genuinely do warrant a prescriber conversation

Most people at week three should simply stay the course. There are a few situations, though, where checking in with a prescriber makes sense rather than waiting. If you're experiencing persistent nausea or vomiting that's making it difficult to eat, drink or function, that's worth flagging, not because the medicine is failing, but because support and timing adjustments can help. If you're not noticing any appetite change whatsoever by weeks five or six at the 0.5 mg dose, your prescriber may want to review whether the titration is on track. And if your lifestyle context has changed significantly since you started (a new medication, a health event, a dramatic shift in diet) that's relevant clinical information. Wegovy is a prescription-only medicine, and the prescriber relationship isn't just for the start of treatment; it exists for exactly these moments. If you're weighing up whether the private route is right for your situation, the Wegovy cost context page covers what a legitimate private prescription typically includes. For a broader look at semaglutide as a treatment, the semaglutide overview covers mechanism, eligibility and what to expect across the full course. If you're ready to talk through your progress with a prescriber, check your eligibility through a free consultation.